Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for GSK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
March 31, 2026 4.540B
December 31, 2025 4.581B
September 30, 2025 4.451B
June 30, 2025 4.959B
March 31, 2025 5.789B
December 31, 2024 4.873B
September 30, 2024 4.308B
June 30, 2024 3.771B
March 31, 2024 5.173B
December 31, 2023 6.606B
September 30, 2023 8.157B
June 30, 2023 8.269B
March 31, 2023 8.624B
December 31, 2022 9.475B
September 30, 2022 7.994B
June 30, 2022 7.933B
March 31, 2022 10.37B
December 31, 2021 5.872B
September 30, 2021 4.738B
June 30, 2021 4.921B
March 31, 2021 6.646B
December 31, 2020 8.707B
September 30, 2020 5.644B
June 30, 2020 10.20B
March 31, 2020 6.020B
Date Value
December 31, 2019 6.340B
September 30, 2019 5.411B
June 30, 2019 5.354B
March 31, 2019 5.490B
December 31, 2018 5.041B
September 30, 2018 5.124B
June 30, 2018 5.561B
March 31, 2018 5.937B
December 31, 2017 5.383B
September 30, 2017 6.692B
June 30, 2017 5.372B
March 31, 2017 5.903B
December 31, 2016 6.354B
September 30, 2016 6.304B
June 30, 2016 7.046B
March 31, 2016 6.650B
December 31, 2015 8.888B
September 30, 2015 9.235B
June 30, 2015 12.12B
March 31, 2015 15.54B
December 31, 2014 7.099B
September 30, 2014 7.107B
June 30, 2014 5.677B
March 31, 2014 6.113B
December 31, 2013 9.532B

Cash and Short Term Investments Definition

Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 7.675B
Johnson & Johnson 22.05B
Eli Lilly & Co. 5.282B
Merck & Co., Inc. 5.773B
Novo Nordisk A/S 3.335B